SCHEMBL4414826

SCHEMBL4414826

N#Cc1ncc(NCCO)nc1N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.44
DRD2 P14416 1/20 0.44
HRH1 P35367 1/20 0.44
KDM4E B2RXH2 3/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
GAA P10253 2/20 0.39
HPGD P15428 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 2/20 0.38
HTR1A P08908 2/20 0.38
DEGS1 O15121 1/20 0.38
POLB P06746 1/20 0.37
HDAC1 Q13547 1/20 0.37
HTR2C P28335 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414964 0.85 GRM2 (0.37) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL5133746 0.80 GRIN2D (0.44) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL4412341 0.74 ALDH1A1 (0.49) KDM4ETP53MAPTKMT2AALDH1A1
SCHEMBL4416447 0.73 MEN1 (0.48) HTR2ADRD2HRH1KDM4ETP53
SCHEMBL4413351 0.70 TDP1 (0.42) HTR2ADRD2KDM4EMAPTKMT2A
SCHEMBL4415007 0.69 KMT2A (0.45) DRD2KDM4ETP53MAPTKMT2A
SCHEMBL4417055 0.69 KMT2A (0.44) DRD2KDM4ETP53MAPTKMT2A
SCHEMBL4413318 0.68 KDM4E (0.46) KDM4EALDH1A1GAAHPGDLMNA
SCHEMBL4415014 0.68 TP53 (0.43) KDM4ETP53MAPTKMT2AALDH1A1
SCHEMBL4417051 0.68 HPGD (0.46) KDM4ETP53MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397351-B1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
EP-1397351-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-17 EP disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 HTR2A 267/4885DRD2 321/4885HRH1 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.